Zhejiang Tailin BioEngineering Co (300813) Fair Value & Analysis
Healthcare · CN · Market cap 2.4B CNY
Fair value as of: Jun 24, 2026
Analysis
Zhejiang Tailin BioEngineering Co (300813) currently trades at ¥19.77, while our model-based Fair Value estimate is ¥2.99 — implying the stock looks roughly 84.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Zhejiang Tailin BioEngineering Co.,Ltd engages in the research and development, production, and sale of microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally. The company primarily offers aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technology products. It also provides pharma processing, such as pharma isolators, high-precision filling and dispensing, sterile transfer; cell and gene therapy; radiopharma; laboratory animal; leak test systems; biodecontamination, including VH2O2 sterilization system and dry fogging system; sterilization monitoring and validation; microbiological testing, comprising sterility and microbial limit test system and pretreatment instruments; and water quality, consisting of microbial monitoring and aquatic organism detection system, total organic carbon (TOC) analysis, enzyme substrate method, and auto…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Zhejiang Tailin BioEngineering Co (300813) undervalued?
What is the fair value of 300813?
What is the quality score of 300813?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.